Image via PR Newswire
Last updated
Cambrex: Geographic Expansion
Cambrex completed initial engineering studies for new large-scale API manufacturing plant expansion in US and Europe
Source: PR Newswire
The leadership read
Market entry of this kind typically deepens demand for biotech & pharma leadership bench strength in the region over the following 12–18 months.
Market context: Against a Talent Market Index of 111.1 (Hot) (up 5.2 month-on-month), EMEA is at easing (-4.4pts) on signal share.
Cambrex: 0 signals in the last 90 days — below the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's EMEA signal flow.
Market entry — the MitchelLake playbook
When a company expands into a new market, the first leadership hires decide whether it lands. A selection of market entries we've run:
Market entry · Oceania
Square
Executive Search Fintech
Market entry
Dropbox
Executive Search for SaaS
Market entry · Asia
Deliveroo
Executive Search in ASEAN
Market entry · Oceania
SurveyMonkey
Managing Director APAC (first hire in region) / Country Manager
Market entry · Asia
LivePerson
Director ASEAN (first hire in region); also Head of Presales APAC
Market entry · Oceania
Etsy
Managing Director, Australia + Asia (MD APAC)
MitchelLake in this thematic
More signals across Biotech & Pharma
Partnership · EMEA
Flagship Pioneering →Flagship Pioneering announced a strategic collaboration with a Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, leveraging national health data capabilities and precision medicine expertise to support Vision 2030.
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim initiated three Phase III clinical trials in precision oncology: two DAREON® programme trials (DAREON®-Lung-1 in SCLC and DAREON®-NEC-1 in epNEC) and Beamion LUNG-3 trial in HER2-mutant NSCLC. This represents advancement of biomarker-informed oncology pipeline.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Product Launch · EMEA
Amgen →European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Ma Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Partnership · EMEA
UCB →UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Intelligence powered by Autonodal ↗